Saturday 17 October 2026
Export CYTOF’s income statement to Excel — free account
Altamira Therapeutics Ltd.
CYTOF Healthcare Biotechnology
Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.
0.09
0.00
0.00%
Follow CYTOF
| Jun '25 | Jun '24 | Jun '23 | Jun '22 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 0.00 | 0.00 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (6.27) | (25.39) | |
P/B ratio |
— | — | 0.00 | 18.75 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 0.00 | 0.00 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (1.94) | (6.37) | |
EV/FCF |
— | — | (1.63) | (5.17) | |
Quick Ratio |
0.09 | 0.37 | 0.20 | 0.10 | |
Current Ratio |
0.11 | 0.43 | 0.32 | 0.20 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
6.04% | 0.00% | 34.34% | 26.07% | |
Debt/Equity |
0.11 | 0.00 | (1.17) | 0.63 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 1.44 | 0.77 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | 0.00 | — | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.65 | 0.57 | 0.63 | 0.86 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | — | (0.13) | (0.06) | |
Graham Number |
— | — | 20.88 | 0.00 | |
Earnings Yield |
— | — | (312.71%) | (28.36%) | |
Free Cash Flow Yield |
— | — | (65.00%) | (19.98%) | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (2.04) | (7.64) | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (2.04) | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(1.38) | (3.20) | (8.58) | (1.59) | |
Working Capital |
(2.06) | (0.70) | (4.05) | (8.21) | |
Capital Expenditures |
— | — | — | (1.59) | |
Net Current Asset Value |
(2.81) | (1.23) | (7.01) | (9.27) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.62 | 0.14 | 0.48 | 0.41 | |
Average Payables |
2.33 | 1.06 | 1.74 | 2.07 | |
Average Assets |
13.90 | 16.87 | 15.22 | 13.85 | |
Average Common Equity |
9.01 | 14.02 | 8.47 | 6.37 |
Columns are period end dates · fundamentals updated 14 Oct 2026